Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Celularity (CELU) EBITDA Margin (2020 - 2025)

Celularity has reported EBITDA Margin over the past 6 years, most recently at 436.66% for Q3 2025.

  • Quarterly results put EBITDA Margin at 436.66% for Q3 2025, down 26347.0% from a year ago — trailing twelve months through Sep 2025 was 348.6% (down 27090.0% YoY), and the annual figure for FY2024 was 106.78%, up 75462.0%.
  • EBITDA Margin for Q3 2025 was 436.66% at Celularity, down from 427.6% in the prior quarter.
  • Over the last five years, EBITDA Margin for CELU hit a ceiling of 1266.58% in Q2 2022 and a floor of 2479.56% in Q3 2023.
  • Median EBITDA Margin over the past 5 years was 173.19% (2024), compared with a mean of 591.05%.
  • Biggest five-year swings in EBITDA Margin: surged 316245bps in 2022 and later tumbled -290776bps in 2023.
  • Celularity's EBITDA Margin stood at 83.2% in 2021, then surged by 805bps to 586.27% in 2022, then tumbled by -90bps to 59.05% in 2023, then tumbled by -3373bps to 1932.56% in 2024, then surged by 77bps to 436.66% in 2025.
  • The last three reported values for EBITDA Margin were 436.66% (Q3 2025), 427.6% (Q2 2025), and 172.84% (Q1 2025) per Business Quant data.